NOVO NORDISK A/S-BNOVO NORDISK A/S-BNOVO NORDISK A/S-B

NOVO NORDISK A/S-B

No trades
See on Supercharts
Market capitalization
‪3.99 T‬DKK
‪83.68 B‬DKK
‪232.26 B‬DKK
‪3.15 B‬
Beta (1Y)
1.50

About NOVO NORDISK A/S-B

CEO
Lars Fruergaard Jørgensen
Headquarters
Bagsværd
Employees (FY)
‪63.37 K‬
Founded
1931
ISIN
DK0062498333
FIGI
BBG000PKHLG5
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

Depending on the exchange, the stock ticker may vary. For instance, on TURQUOISE exchange NOVO NORDISK A/S-B stocks are traded under the ticker NOVOBC.
NOVO NORDISK A/S-B is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
NOVOBC earnings for the last quarter are 5.00 DKK per share, whereas the estimation was 4.81 DKK resulting in a 4.02% surprise. The estimated earnings for the next quarter are 4.58 DKK per share. See more details about NOVO NORDISK A/S-B earnings.
NOVO NORDISK A/S-B revenue for the last quarter amounts to ‪58.73 B‬ DKK despite the estimated figure of ‪57.78 B‬ DKK. In the next quarter revenue is expected to reach ‪62.62 B‬ DKK.
Yes, you can track NOVO NORDISK A/S-B financials in yearly and quarterly reports right on TradingView.
NOVOBC net income for the last quarter is ‪21.96 B‬ DKK, while the quarter before that showed ‪22.48 B‬ DKK of net income which accounts for −2.29% change. Track more NOVO NORDISK A/S-B financial stats to get the full picture.
NOVO NORDISK A/S-B dividend yield was 1.35% in 2023, and payout ratio reached 50.35%. The year before the numbers were 1.32% and 50.59% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, NOVOBC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVO NORDISK A/S-B stock right from TradingView charts — choose your broker and connect to your account.
NOVOBC reached its all-time high on Mar 7, 2024 with the price of 929.5 DKK, and its all-time low was 62.7 DKK and was reached on Dec 12, 2011.
See other stocks reaching their highest and lowest prices.
As of Apr 25, 2024, the company has ‪63.37 K‬ employees. See our rating of the largest employees — is NOVO NORDISK A/S-B on this list?
We've gathered analysts' opinions on NOVO NORDISK A/S-B future price: according to them, NOVOBC price has a max estimate of 1141.42 DKK and a min estimate of 530.00 DKK. Read a more detailed NOVO NORDISK A/S-B forecast: see what analysts think of NOVO NORDISK A/S-B and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVO NORDISK A/S-B EBITDA is ‪111.87 B‬ DKK, and current EBITDA margin is 47.96%. See more stats in NOVO NORDISK A/S-B financial statements.